These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 25999488

  • 1. The drug push.
    Servick K.
    Science; 2015 May 22; 348(6237):850-3. PubMed ID: 25999488
    [No Abstract] [Full Text] [Related]

  • 2. A new antibiotic and the evolution of resistance.
    Arias CA, Murray BE.
    N Engl J Med; 2015 Mar 19; 372(12):1168-70. PubMed ID: 25785976
    [No Abstract] [Full Text] [Related]

  • 3. Fix the antibiotics pipeline.
    Cooper MA, Shlaes D.
    Nature; 2011 Apr 07; 472(7341):32. PubMed ID: 21475175
    [No Abstract] [Full Text] [Related]

  • 4. Drug development: Time for teamwork.
    May M.
    Nature; 2014 May 01; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M, Mossialos E.
    Expert Opin Drug Discov; 2018 Oct 01; 13(10):889-892. PubMed ID: 30175625
    [No Abstract] [Full Text] [Related]

  • 8. Antibacterial R&D incentives.
    Laxminarayan R, Powers JH.
    Nat Rev Drug Discov; 2011 Sep 30; 10(10):727-8. PubMed ID: 21959280
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The drug-resistant bacteria that pose the greatest health threats.
    Willyard C.
    Nature; 2017 Feb 28; 543(7643):15. PubMed ID: 28252092
    [No Abstract] [Full Text] [Related]

  • 11. Oleamycins A and B: new antibacterial cyclic hexadepsipeptides isolated from a terrestrial Streptomyces sp.
    Raju R, Gromyko O, Andriy B, Fedorenko V, Luzhetskyy A, Müller R.
    J Antibiot (Tokyo); 2014 Apr 28; 67(4):339-43. PubMed ID: 24448627
    [No Abstract] [Full Text] [Related]

  • 12. David Haslam. Interview by Asher Mullard.
    Haslam D.
    Nat Rev Drug Discov; 2013 Jul 28; 12(7):500. PubMed ID: 23764976
    [No Abstract] [Full Text] [Related]

  • 13. A three-step plan for antibiotics.
    Nature; 2014 May 29; 509(7502):533. PubMed ID: 24877183
    [No Abstract] [Full Text] [Related]

  • 14. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
    Simpkin VL, Renwick MJ, Kelly R, Mossialos E.
    J Antibiot (Tokyo); 2017 Dec 29; 70(12):1087-1096. PubMed ID: 29089600
    [Abstract] [Full Text] [Related]

  • 15. Incentives aim to boost antibiotic development.
    Roberts JP.
    Nat Biotechnol; 2012 Aug 29; 30(8):735. PubMed ID: 22871701
    [No Abstract] [Full Text] [Related]

  • 16. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure.
    Spellberg B, Sharma P, Rex JH.
    Nat Rev Drug Discov; 2012 Feb 01; 11(2):168. PubMed ID: 22293569
    [No Abstract] [Full Text] [Related]

  • 17. MBJ-0086 and MBJ-0087, new bicyclic depsipeptides, from Sphaerisporangium sp. 33226.
    Kawahara T, Itoh M, Izumikawa M, Hashimoto J, Sakata N, Tsuchida T, Shin-ya K.
    J Antibiot (Tokyo); 2015 Jan 01; 68(1):67-70. PubMed ID: 25095808
    [No Abstract] [Full Text] [Related]

  • 18. Market watch: Biopharma deal-making in 2014: a record year for M&A value.
    Micklus A, Muntner S.
    Nat Rev Drug Discov; 2015 Feb 01; 14(2):84-5. PubMed ID: 25633786
    [No Abstract] [Full Text] [Related]

  • 19. In the midst of the antimicrobial discovery conundrum: an overview.
    Tomaras AP, Dunman PM.
    Curr Opin Microbiol; 2015 Oct 01; 27():103-7. PubMed ID: 26356257
    [No Abstract] [Full Text] [Related]

  • 20. The $2.6 billion pill--methodologic and policy considerations.
    Avorn J.
    N Engl J Med; 2015 May 14; 372(20):1877-9. PubMed ID: 25970049
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.